Robert L. Coleman, MD, opens discussion on a second patient case and highlights critical aspects of mismatch repair deficient (dMMR) recurrent endometrial carcinoma.
Videos
Before closing out their discussion on the first patient case, key opinion leaders on endometrial carcinoma reflect on the optimal selection and sequencing of therapy in pMMR recurrent disease.
Chad Tang, MD, discusses currently available treatment options and recent research in the prostate cancer space.
John Allan, MD, provides insights on novel agents and treatment strategies currently being studied in chronic lymphocytic leukemia.
An expert hematologist-oncologist offers advice for community oncologists who are treating patients with newly diagnosed chronic lymphocytic leukemia.
An overview of assessing risk of disease recurrence, steps taken to minimize recurrence, and when to consider second-line treatment for patients with CLL.
An expert on CLL reviews recent data updates from studies of BTK inhibitors in the frontline setting.
Mathew R. Smith, MD, PhD closes the discussion by sharing clinical pearls for community oncologists and highlights unmet needs in the CRPC landscape.
Dr. Smith presents key data concerning the use of darolutamide in patients with castration-resistant CRPC, with a focus on safety and patient quality of life.
John Allan, MD, an expert on chronic lymphocytic leukemia, details adverse events seen with venetoclax and obinutuzumab.
An expert on chronic lymphocytic leukemia reviews the CLL14 trial, evaluating venetoclax plus obinutuzumab in patients with previously untreated CLL.
Melanie Goldfarb, MD, MSc, FACS, FACE, discusses the current treatment landscape for patients with thyroid cancer.
John P. Diaz, MD, explains the importance of the topics to be discusses at the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.
Neeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.
John P. Diaz, MD, provides an overview of the topics to be discusses during the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.
Closing out his review of HR+/HER2-low metastatic breast cancer management, Kevin Kalinsky, MD, considers unmet needs and ongoing investigation into novel treatment strategies.
Comprehensive insight to the treatment armamentarium for patients with HR+/HER2-low metastatic breast cancer and factors that help inform optimal sequencing.
Expert oncologist Kevin Kalinsky, MD, reviews the diagnosis and management of a 65-year old woman with HR+/HER2-low metastatic breast cancer.
Hatem Soliman, MD, explains how to test for HER2 status in patients with breast cancer.
Ruta D. Rao, MD, discussed the trial design and final efficacy results of the ASCENT trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer.
Edwin Choy, MD, discusses adjuvant treatments for patients with gastrointestinal stromal tumors.
Richard D. Carvajal, MD, discusses what he sees as the leading factors in making outcomes worse for patients with mucosal melanoma and how the disease differs from treatment for patients with cutaneous melanoma.
Eytan M. Stein, MD, provides community oncologists with an overview of the unmet needs in the acute myeloid leukemia space and provides recommendations for those treating patients with this disease.
Wesley Burkett, MD, discusses some novel targets that are available and being evaluated in the endometrial cancer space.
Carolyn Owen, MD, discusses emerging and exciting data in the chronic lymphocytic leukemia space.
Expert panelists provide their perspective on the real-world use of combination lenvatinib + pembrolizumab in patients with MMRp recurrent endometrial carcinoma.
Moderator Robert L. Coleman, MD, spearheads a review of clinical data from KEYNOTE 775, which combined lenvatinib with pembrolizumab in patients with endometrial carcinoma.
Yousef Zakharia, MD, discusses the COSMIC-313 study and its implications to date.
Samer A. Srour, MD, discusses Orca Q graft and how it’s revolutionized haploidentical allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
Expert panelist provides his perspective on a CRPC patient case before discussing the typical course of treatment for patients with nonmetastatic CRPC.